Cell line-specific modulation of colorectal cancer cell behavior following SGLT2 inhibition via empagliflozin
Abstract
Abstract Colorectal cancer (CRC) is a major global health problem, with type 2 diabetes mellitus (T2DM) and obesity among its significant risk factors. Empagliflozin (EMPA), a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor widely used in the treatment of T2DM, has also demonstrated potential anticancer effects. However, reports of possible adverse effects in certain oncological contexts have raised concerns. We established several in vitro assays to evaluate the effects of EMPA on different colon cancer–derived cell lines. We applied proliferation, wound-healing, colony-formation, and CCK-8 assays, together with measurements of EMPA and glucose consumption, in HCT116, HT29, DLD1, SW480, and LS180 CRC cell lines. SGLT2 expression was confirmed in all cell lines. EMPA reduced proliferation in HT29 cells. Clonogenicity was decreased in HT29 and HCT116, but increased in DLD1 and SW480. Migration was reduced in DLD1, whereas enhanced migratory potential was observed in HT29 and HCT116. Cell viability was not significantly affected at the tested concentrations. HT29 cells showed significantly higher EMPA consumption compared with other lines. Glucose consumption differed among cell lines but was not altered by EMPA treatment. LS180 cells showed no significant response in the assessed parameters. EMPA was associated with ambivalent, cell line-specific effects on CRC cell behavior. While antitumor activity was observed in some models, enhanced migration and clonogenicity…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.